Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2b study of JNJ-64304500 in moderately to severely active Crohn's disease
2016-000634-21Phase 2Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Jul 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of NNC0142-0002 in Crohn's disease (3 arms), sponsored by Janssen Pharmaceutical. Primary endpoint: Change from baseline in Crohn's Disease Activity Index score at Week 8. Started Jul 2016; status: completed.
02
Drugs
NNC0142-0002
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on 2016-000634-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-000634-21.